Torrent Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 5/6
Torrent Pharmaceuticals has a total shareholder equity of ₹67.1B and total debt of ₹44.9B, which brings its debt-to-equity ratio to 66.9%. Its total assets and total liabilities are ₹147.4B and ₹80.4B respectively. Torrent Pharmaceuticals's EBIT is ₹24.2B making its interest coverage ratio 6.6. It has cash and short-term investments of ₹7.9B.
Key information
66.9%
Debt to equity ratio
₹44.89b
Debt
| Interest coverage ratio | 6.6x |
| Cash | ₹7.90b |
| Equity | ₹67.07b |
| Total liabilities | ₹80.37b |
| Total assets | ₹147.44b |
Recent financial health updates
Does Torrent Pharmaceuticals (NSE:TORNTPHARM) Have A Healthy Balance Sheet?
Mar 03
Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Rather Sparingly
Nov 14Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly
Jun 01Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly
Mar 01Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly
Jul 25Here's Why Torrent Pharmaceuticals (NSE:TORNTPHARM) Can Manage Its Debt Responsibly
Jan 04Recent updates
Torrent Pharmaceuticals Limited's (NSE:TORNTPHARM) P/E Is On The Mark
Apr 16Does Torrent Pharmaceuticals (NSE:TORNTPHARM) Have A Healthy Balance Sheet?
Mar 03Torrent Pharmaceuticals (NSE:TORNTPHARM) Is Increasing Its Dividend To ₹22.00
Feb 05Investors Interested In Torrent Pharmaceuticals Limited's (NSE:TORNTPHARM) Earnings
Jan 07Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Rather Sparingly
Nov 14Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly
Jun 01Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly
Mar 01Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly
Jul 25Torrent Pharmaceuticals' (NSE:TORNTPHARM) Soft Earnings Don't Show The Whole Picture
Jun 02Estimating The Fair Value Of Torrent Pharmaceuticals Limited (NSE:TORNTPHARM)
May 25A Look At The Intrinsic Value Of Torrent Pharmaceuticals Limited (NSE:TORNTPHARM)
Feb 18Torrent Pharmaceuticals (NSE:TORNTPHARM) Is Increasing Its Dividend To ₹25.00
Jan 27Here's Why Torrent Pharmaceuticals (NSE:TORNTPHARM) Can Manage Its Debt Responsibly
Jan 04Here's Why I Think Torrent Pharmaceuticals (NSE:TORNTPHARM) Is An Interesting Stock
Dec 14A Look At The Fair Value Of Torrent Pharmaceuticals Limited (NSE:TORNTPHARM)
Nov 07Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly
Sep 30Does Torrent Pharmaceuticals (NSE:TORNTPHARM) Deserve A Spot On Your Watchlist?
Sep 01Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly
Jul 02I Ran A Stock Scan For Earnings Growth And Torrent Pharmaceuticals (NSE:TORNTPHARM) Passed With Ease
Jun 01Torrent Pharmaceuticals Limited (NSE:TORNTPHARM) Shares Could Be 30% Above Their Intrinsic Value Estimate
May 14Does Torrent Pharmaceuticals (NSE:TORNTPHARM) Have A Healthy Balance Sheet?
Mar 23The Torrent Pharmaceuticals (NSE:TORNTPHARM) Share Price Has Gained 84% And Shareholders Are Hoping For More
Mar 02Is It Smart To Buy Torrent Pharmaceuticals Limited (NSE:TORNTPHARM) Before It Goes Ex-Dividend?
Feb 10Do Torrent Pharmaceuticals's (NSE:TORNTPHARM) Earnings Warrant Your Attention?
Jan 19Should You Be Impressed By Torrent Pharmaceuticals Limited's (NSE:TORNTPHARM) ROE?
Dec 29Is Torrent Pharmaceuticals (NSE:TORNTPHARM) Using Too Much Debt?
Dec 08
Investors Who Bought Torrent Pharmaceuticals (NSE:TORNTPHARM) Shares Three Years Ago Are Now Up 118%
Nov 16The Torrent Pharmaceuticals Limited (NSE:TORNTPHARM) Second-Quarter Results Are Out And Analysts Have Published New Forecasts
Oct 28Here's Why We Think Torrent Pharmaceuticals (NSE:TORNTPHARM) Is Well Worth Watching
Oct 07Torrent Pharmaceuticals Limited (NSE:TORNTPHARM) Delivered A Better ROE Than Its Industry
Sep 16Financial Position Analysis
Short Term Liabilities: TORNTPHARM's short term assets (₹52.9B) exceed its short term liabilities (₹49.0B).
Long Term Liabilities: TORNTPHARM's short term assets (₹52.9B) exceed its long term liabilities (₹31.4B).
Debt to Equity History and Analysis
Debt Level: TORNTPHARM's net debt to equity ratio (55.2%) is considered high.
Reducing Debt: TORNTPHARM's debt to equity ratio has reduced from 120.3% to 66.9% over the past 5 years.
Debt Coverage: TORNTPHARM's debt is well covered by operating cash flow (63.9%).
Interest Coverage: TORNTPHARM's interest payments on its debt are well covered by EBIT (6.6x coverage).